I beleive that DM has at least two deals that he is working on. The first is the licensing deal that he has openly mentioned for the past year with Resverlogix RVX 208 and the other involves Zenith.

I think with RVX 208, there is no way that DM will settle for anything less then $2.67 (the Hepalink price) because then that Hepalink deal will have to be modified to compensate them for a lower price. The puzzeling question is, if there was a deal on the table for the next meeting, why are the insiders purchasing shares? This would not be allowed by the SEC. Therefore I think a licensing deal is at least six months away.

So why would you pospone the AGM's of both Resverlogix and Zenith? DM has always said that he valued the Shares of Zenith at $1.00 US and did a equity raise last year at $1.00 US which establishes that. Since then, there has been advancements in the trials at Zenith and this has been presented at dog and pony shows. So it is my opinon, it is something with Zenith which is the reason for the change in AGM date and not the licensing deal with RVX 208. This is why the insiders at Resverlogix are able to purchase shares in Resverlogix with out causing problems with the SEC.

If DM was to get a partner on one of the Zenith trials, I am sure the Nasdaq would view this as a reasonable platform to issue a listing which DM has stated he is pursuing. With a senario like this occuring the value of Resverlogix would increase because of the link between the two. JMHO.